Purpose <p>This review synthesizes current research from Irreversible electroporation in Ovarian Cancer regarding the expanding roles of electroporation in ovarian cancer. It addresses how controlled electric fields can overcome late-stage diagnosis, chemoresistance, and the immunosuppressive tumor microenvironment.</p> Methods <p>The literature on reversible and irreversible electroporation was comprehensively reviewed within Irreversible electroporation in Ovarian Cancer. Advancements across direct tissue ablation, electrochemotherapy, immunotherapy gene delivery, CRISPR-Cas9 somatic mouse modeling, and exosome drug delivery systems were analyzed.</p> Results <p>The findings from Irreversible electroporation in Ovarian Cancer demonstrate that high-frequency irreversible electroporation and nanosecond pulsed electric fields ablate resilient ovarian cancer-initiating cells and induce apoptosis non-thermally, safeguarding surrounding vital structures. Combining reversible electroporation with low-permeant cytotoxic drugs significantly increases cytotoxicity in cisplatin-resistant cells. Additionally, electroporation serves as an efficient non-viral transfection method to produce mRNA-loaded dendritic cell vaccines and transient CAR-T or CAR-NK therapies. In preclinical settings, in vivo fallopian tube electroporation successfully delivers CRISPR-Cas9 to accurately replicate metastatic disease. However, optimization challenges remain regarding pulse parameters and electrical nuances like bipolar cancellation.</p> Conclusion <p>Irreversible electroporation has evolved into a vital, non-thermal cornerstone for ovarian cancer therapy and research. While providing a versatile platform for targeted ablation, chemotherapy sensitization, and advanced modeling, larger clinical trials are required to standardize delivery protocols for widespread clinical translation.</p>